Researchers at the Hawaiian Eye and Retina meeting in Maui has reported positive 6-month results for RGX-314, for the treatment of wet AMD, using a… Read More »Phase 2 interim data for RGX-314 treatment for wet AMD reports stable BCVA and CRT at six months.
Researchers at the University of Nevada, Reno School of Medicine and the Department of Ophthalmology, Weill Cornell Medical College, New York-Presbyterian Hospital, has published safety… Read More »Phase 1 study results published in the Lancet report stable vision following a single dose gene therapy encoding anti-VEGF protein.
Researchers at UCL and Moorfields Eye Hospital, UK, have reported clinical research using artificial intelligence (AI) tools to identify at-risk neonates of retinopathy of prematurity… Read More »Clinical research at UCL and Moorfields on AI tools to identify at-risk neonates of retinopathy of prematurity (ROP).
A recent update on phase 2 clinical research of a novel treatment for patients of Stargardt disease has reported a positive primary end-point slowing the… Read More »Clinical research on a novel oral therapy for Stargardt disease suggests uses a deuterated form of vitamin A.
Researchers at the Institute for Vision Research, University of Iowa, USA, and Ophthalmology and Visual Sciences, Duke-NUS Graduate Medical School, Singapore, have reported a publication… Read More »Research on clinical trial outcomes for XLRS have proposed prolonged trial periods in order to assess disease stabilization.
At the recent 23rd EURETINA Congress on October 8th in Amsterdam, the Netherlands, Professor Richard Gale, based at the Hull York Medical School, University of… Read More »EURETINA Congress presentation on patient mental health and caregiver burden in AMD.
Clinical researchers from the US, Canada and the Netherlands, have reported a study to recommend clinical trial designs and outcomes for XLRP (X-linked retinitis pigmentosa). … Read More »Clinical trial development and trial outcome measures have published recommendations for XLRP studies.
Principal investigators Dr. Aaron Nagiel, MD, PhD, at Children’s Hospital of Los Angeles, and Dr. Lesley Everett, MD, PhD, MPhil, at the Oregon Health Sciences… Read More »Clinical researchers on X-linked retinoschisis (XLRS) reports the dosing of a first patient in a phase 1 / 2 study.
FDA approval of visual gains and safety of aflibercept (8mg) were announced on August 18th, indicated for the treatment of patients with wet age-related macular… Read More »Aflibercept (8mg) has been approved for wet AMD, diabetic macular edema (DME) and diabetic retinopathy (DR).
Results of a biosimilar agent (SB15) of aflibercept (Eylea) have reported comparable outcomes between the generic version and the reference drug (aflibercept) for naïve neovascular… Read More »A biosimilar of aflibercept (“SB15”) indicates comparability to the reference drug for neovascular AMD.
